Tesaro Inc (TSRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Tesaro Inc (Tesaro) is an oncology-focused biopharmaceutical company. It focuses on acquiring, in-licensing, developing and commercializing cancer therapeutics and supportive care products. VARUBI, the company’s first commercial product is approved for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Tesaro’s development portfolio includes novel cancer and supportive care product candidates in various development stages. The company harnesses its immune oncology platform to treat numerous cancers. It operates subsidiaries in the US, the UK and Switzerland. Tesaro is headquartered in Waltham, Massachusetts, the US.
Tesaro Inc Key Recent Developments
Nov 03, 2016: TESARO Announces Third-Quarter 2016 Operating Results
Aug 04, 2016: Tesaro Announces Second-Quarter 2016 Operating Results
May 05, 2016: TESARO Announces First-Quarter 2016 Operating Results
Apr 04, 2016: TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors
Feb 25, 2016: TESARO Announces Fourth-Quarter 2015 Operating Results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Tesaro Inc - Key Facts 6
Tesaro Inc - Key Employees 7
Tesaro Inc - Key Employee Biographies 8
Tesaro Inc - Major Products and Services 9
Tesaro Inc - Pharmaceutical Pipeline Products Data 10
Tesaro Inc, Pipeline Products by Therapy Area 10
Tesaro Inc, Pipeline Products by Development Phase 11
Tesaro Inc - History 13
Tesaro Inc - Company Statement 15
Tesaro Inc - Locations And Subsidiaries 18
Head Office 18
Section 2 – Company Analysis 19
Tesaro Inc - Business Description 19
Tesaro Inc - Corporate Strategy 20
Tesaro Inc - SWOT Analysis 21
SWOT Analysis - Overview 21
Tesaro Inc - Strengths 21
Tesaro Inc - Weaknesses 22
Tesaro Inc - Opportunities 23
Tesaro Inc - Threats 24
Tesaro Inc - Key Competitors 25
Section 3 – Company Financial Ratios 26
Financial Ratios - Capital Market Ratios 26
Financial Ratios - Annual Ratios 27
Performance Chart 29
Financial Performance 29
Financial Ratios - Interim Ratios 30
Financial Ratios - Ratio Charts 31
Section 4 – Company’s Lifesciences Financial Deals and Alliances 32
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 33
Tesaro Inc, Recent Deals Summary 34
Section 5 – Company’s Recent Developments 35
Nov 03, 2016: TESARO Announces Third-Quarter 2016 Operating Results 35
Aug 04, 2016: Tesaro Announces Second-Quarter 2016 Operating Results 37
May 05, 2016: TESARO Announces First-Quarter 2016 Operating Results 39
Apr 04, 2016: TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors 41
Feb 25, 2016: TESARO Announces Fourth-Quarter 2015 Operating Results 42
Jan 11, 2016: TESARO Outlines Business Priorities and Strategic Outlook for 2016 44
Dec 14, 2015: TESARO Added to the NASDAQ Biotechnology Index 46
Oct 29, 2015: TESARO Announces Third-Quarter 2015 Operating Results 47
Sep 21, 2015: Tesaro Appoints Martin Huber, M.D., As Senior Vice President And Chief Medical Officer 48
Aug 06, 2015: TESARO Announces Second-Quarter 2015 Operating Results 49
Section 6 – Appendix 51
Methodology 51
Ratio Definitions 51
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Tables
Tesaro Inc, Key Facts 6
Tesaro Inc, Key Employees 7
Tesaro Inc, Key Employee Biographies 8
Tesaro Inc, Major Products and Services 9
Tesaro Inc, Number of Pipeline Products by Therapy Area 10
Tesaro Inc, Number of Pipeline Products by Development Stage 11
Tesaro Inc, Pipeline Products By Therapy Area and Development Phase 12
Tesaro Inc, History 13
Tesaro Inc, Key Competitors 25
Tesaro Inc, Ratios based on current share price 26
Tesaro Inc, Annual Ratios 27
Tesaro Inc (Cont...1), Annual Ratios 28
Tesaro Inc, Interim Ratios 30
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 33
Tesaro Inc, Recent Deals Summary 34
Currency Codes 51
Capital Market Ratios 51
Equity Ratios 52
Profitability Ratios 52
Cost Ratios 53
Liquidity Ratios 53
Leverage Ratios 53
Efficiency Ratios 54
List of Figures
Tesaro Inc, Pipeline Products by Therapy Area 10
Tesaro Inc, Pipeline Products by Development Phase 11
Tesaro Inc, Performance Chart (2011 - 2015) 29
Tesaro Inc, Ratio Charts 31
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 32
Tesaro Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 33